Grandomics
Grandomics (Hope Group) is a provider of third-generation long-read sequencing services and bioinformatics solutions, operating as a pioneer in long-read sequencing data technology and applications. The company operates four business modules: scientific services, medical diagnosis, bioinformatics, and advanced manufacturing. Grandomics has established over 5,000 square meters of research service platforms and…
Funding snapshot
About
Grandomics (Hope Group) is a provider of third-generation long-read sequencing services and bioinformatics solutions, operating as a pioneer in long-read sequencing data technology and applications. The company operates four business modules: scientific services, medical diagnosis, bioinformatics, and advanced manufacturing. Grandomics has established over 5,000 square meters of research service platforms and medical testing laboratories in Beijing and Wuhan, equipped with advanced technology platforms including ONT PromethION 48, PacBio Sequel II, MGISEQ2000 and T7, and Bionano Saphyr optical mapping. Scientific services include whole genome survey, de novo sequencing, whole genome resequencing, pan-genome analysis, full-length cDNA and RNA sequencing, single-cell transcriptomics, metagenomics, and mitochondrial and chloroplast genome completion. Medical diagnosis services cover genetic disease diagnosis through WES, WGS, and third-generation whole genome sequencing, DMD full-length detection, FSHD testing, Bionano for assisted reproduction and leukemia fusion gene diagnosis, and pathogen detection through mTGS, mNGS, and Nanopore multiplex respiratory pathogen diagnosis. The company has developed proprietary software including NextDenovo and NextPolish assembly tools, GrandVariants for structural variation analysis, GrandPathogen for pathogen detection, GrandBox for genetic disease big data analysis, and the dbSV human genome structural variation database. Grandomics has been listed in the Nature Index annual rankings from 2020 to 2024. Founded in 2011 and headquartered in Haidian, China, the company has raised $29.6M in Series B funding from investors including Matrix Partners China, Zero2IPO Ventures, SAIF Partners, Marathon Venture Partners, and Beijing Changping Science and Technology Park Development.
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Genomics > Sequencing Analysis,
Genomics > Genomics Services > Full Service,
Life Sciences Platforms and Tools > Research Services > Genomics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.